Sign In

Chris Molloy

CEO at Medicines Discovery Catapult ; Independent chair UK COVID-19 Rapid Test Consortium ; Non-exec chairman at Exploristics Ltd and NorthWest EHealth Ltd

Chris Molloy is a seasoned professional with national programme, non-executive director (NED), and executive leadership experience across various sectors including biotech, diagnostics, software, pharma, and advisory.

His specialties lie in managing start-ups, mission-critical projects, and rescue projects within life sciences, pharma, biotech, diagnostics, software, and digital healthcare domains.

He has held international positions focusing on strategic business planning, fundraising, professional services, deal-making, sales execution, investor relations, and marketing communications, particularly in Asia-Pacific regions.

With a diverse background, Chris Molloy is known for his expertise in industry and academia, demonstrated through executive team creation and investment initiatives in life sciences.

His psychometric profiles reveal an ENFP Myers Briggs type and an I-D DISC profile.

Education-wise, Chris has studied at The University of Manchester, University of Bradford for his Bachelor of Science, The Oratory School, and also pursued a Masters degree at The Institute of Directors.

Throughout his career, Chris has held prominent roles such as CEO at Medicines Discovery Catapult, Chair of the National Industry Consortium for COVID-19 mass testing diagnostics at the Department of Health and Social Care, and Non-Executive Chairman at organizations like NorthWest EHealth and Exploristics.

He has also served as the Founding National Program Director at the UK Lighthouse Lab Network, CEO at The RSA Group, Non-Executive Director at RSA Executive Search, VP Corporate Development & Marketing at IDBS, COO at MerLion Pharmaceuticals, and Research Manager at GlaxoSmithKline.

Highlights

Nov 2 · linkedin

More evidence that we must attack #AMR with pace and purpose. Thanks to University of Sydney & National Health and Medical Research Council (NHMRC) This needs global #team science & translation. PACE-AMR is a new £30m R&D programme giving wrap-around support to pioneers in targeted amr #drugdiscovery and #diagnostics R&D Innovate UK Medicines Discovery Catapult LifeArc Catapult Network #getPACEy

Sep 30 · linkedin

Consented health data are a critical national resource for UK innovators. We owe it to patients who consent, and patients to come, to use it to develop the next generations of medicines Matt Hancock James Bethell Medicines Discovery Catapult L. Mitchell Hakim Yadi Ph.D. OBE

Chris Molloy
Add to my network

Location

Watford, England, United Kingdom